董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Peter Moldt | 男 | Director | 61 | 未披露 | 未持股 | 2020-06-30 |
| Thomas Woiwode | 男 | Director | 48 | 未披露 | 未持股 | 2020-06-30 |
| Carole Nuechterlein | 女 | Director | 59 | 未披露 | 未持股 | 2020-06-30 |
| Lawrence M. Blatt | 男 | Chief Executive Officer and Director | 58 | 67.44万美元 | 未持股 | 2020-06-30 |
| Leonid Beigelman | 男 | President and Director | 62 | 55.50万美元 | 未持股 | 2020-06-30 |
| Kathleen Sereda Glaub | 女 | Director | 67 | 0.50万美元 | 未持股 | 2020-06-30 |
| K. Peter Hirth | 男 | Director | 69 | 3.00万美元 | 未持股 | 2020-06-30 |
| Jack B. Nielsen | 男 | Chair and Director | 56 | 未披露 | 未持股 | 2020-06-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lawrence M. Blatt | 男 | Chief Executive Officer and Director | 58 | 67.44万美元 | 未持股 | 2020-06-30 |
| Leonid Beigelman | 男 | President and Director | 62 | 55.50万美元 | 未持股 | 2020-06-30 |
| Lesley Ann Calhoun | 女 | Executive Vice President, Chief Financial Officer | 54 | 未披露 | 未持股 | 2020-06-30 |
| Lucinda Y. Quan | 女 | Executive Vice President, Chief Business Officer and General Counsel | 48 | 44.43万美元 | 未持股 | 2020-06-30 |
| Julian A. Symons | 男 | Executive Vice President, Chief Scientific Officer | 59 | 未披露 | 未持股 | 2020-06-30 |
董事简历
中英对照 | 中文 | 英文- Peter Moldt
-
Peter Moldt，自2015年1月起担任董事；自2012年起担任Novo Ventures US Inc.（为Novo A/S提供特定咨询服务）的合伙人， Novo A/S是丹麦一家有限责任公司，管理投资和金融资产；2009年至2012年5月间担任Novo A/S的合伙人。他成立了Curalogic A/S（丹麦一家上市的制药公司），并于2004年至2009年清算期间担任其首席执行官。他于2000年至2004年间担任7TM Pharma A/S（私营生物技术公司，由他联合成立）的首席运营官。在此前的11年间，他在NeuroSearch A/S（丹麦上市生物技术公司）担任了多个职位，包括药物研发主管，负责潜伏期和临床药物研发的各个方面。他获得了the Royal Danish School of Pharmacy的药学和药物化学硕士和博士学位。他也是Yale University in the Department of Organic Chemistry的博士后。
Peter Moldt has served as chairman of our board of directors since September 2016. Since May 2012 Dr. Moldt has been employed as a Senior Partner at Novo Ventures US Inc., which provides certain consultancy services to Novo Holdings A/S, a Danish limited liability company that manages investments and financial assets. From 2009 to 2012 Dr. Moldt served as Partner of Novo Holdings A/S. From 2004 to 2009 Dr. Moldt served as Chief Executive Officer of Curalogic A/S, a publicly listed Danish pharmaceutical company which Dr. Moldt founded. From 2000 to 2004 Dr. Moldt served as Chief Operating Officer of 7TM Pharma A/S, a private biotechnology company which Dr. Moldt co-founded. From 1989 to 2000 Dr. Moldt held various positions with NeuroSearch A/S, a publicly listed Danish biotechnology company. Dr. Moldt currently serves on the boards of directors of several private biotechnology and biopharmaceutical companies. He received an M.Sc. and a Ph.D. in Pharmacy and Medicinal Chemistry from the Royal Danish School of Pharmacy. Dr. Moldt also served as a post-doc with Yale University’s department of organic chemistry. - Peter Moldt，自2015年1月起担任董事；自2012年起担任Novo Ventures US Inc.（为Novo A/S提供特定咨询服务）的合伙人， Novo A/S是丹麦一家有限责任公司，管理投资和金融资产；2009年至2012年5月间担任Novo A/S的合伙人。他成立了Curalogic A/S（丹麦一家上市的制药公司），并于2004年至2009年清算期间担任其首席执行官。他于2000年至2004年间担任7TM Pharma A/S（私营生物技术公司，由他联合成立）的首席运营官。在此前的11年间，他在NeuroSearch A/S（丹麦上市生物技术公司）担任了多个职位，包括药物研发主管，负责潜伏期和临床药物研发的各个方面。他获得了the Royal Danish School of Pharmacy的药学和药物化学硕士和博士学位。他也是Yale University in the Department of Organic Chemistry的博士后。
- Peter Moldt has served as chairman of our board of directors since September 2016. Since May 2012 Dr. Moldt has been employed as a Senior Partner at Novo Ventures US Inc., which provides certain consultancy services to Novo Holdings A/S, a Danish limited liability company that manages investments and financial assets. From 2009 to 2012 Dr. Moldt served as Partner of Novo Holdings A/S. From 2004 to 2009 Dr. Moldt served as Chief Executive Officer of Curalogic A/S, a publicly listed Danish pharmaceutical company which Dr. Moldt founded. From 2000 to 2004 Dr. Moldt served as Chief Operating Officer of 7TM Pharma A/S, a private biotechnology company which Dr. Moldt co-founded. From 1989 to 2000 Dr. Moldt held various positions with NeuroSearch A/S, a publicly listed Danish biotechnology company. Dr. Moldt currently serves on the boards of directors of several private biotechnology and biopharmaceutical companies. He received an M.Sc. and a Ph.D. in Pharmacy and Medicinal Chemistry from the Royal Danish School of Pharmacy. Dr. Moldt also served as a post-doc with Yale University’s department of organic chemistry.
- Thomas Woiwode
-
Thomas Woiwode，从2013年7月起担任我们董事会成员。Woiwode 博士2002年起在Versant Ventures担任不同的职位，2011年起担任投资合伙人；2014年7月起担任总经理。他曾在这段时间里担任许多运营职位，最近担任Okairos首席运营官。Woiwode 博士还在Versant Ventures联合创立了一家独资生物技术孵化器，为三个在Versant创立的生物技术公司担任创始首席商务官。他还曾在XenoPort, Inc.担任演技科学家；他还在数个私有企业董事会任职。Woiwode博士持有California 大学Berkeley 分校的文学士和理学位以及斯坦福大学的博士学位。
Thomas Woiwode has served as the chairman of our board of directors since May 2019. Dr. Woiwode has been with Versant Venture Management, LLC, or Versant Ventures, a healthcare investment firm, since 2002 in various capacities, serving as a managing director since July 2014 and previously as a venture partner from June 2011 to July 2014. He has also served in a number of operating roles over this time, most recently as the chief operating officer of Okairos AG, or Okairos, a biopharmaceutical company developing genetic vaccines for major infectious diseases, from April 2011 until May 2013. Prior to Okairos, Dr. Woiwode co-founded EuroVentures, a wholly owned biotechnology incubator within Versant Ventures, and in this role, served as the founding chief business officer for three biotechnology companies created within Versant Ventures. Before joining Versant Ventures, Dr. Woiwode also served as a research scientist at XenoPort, Inc. Dr. Woiwode serves on the board of directors of several private companies and on the board of directors of four public companies, Adverum Biotechnologies, Inc., Aligos Therapeutics, Inc., Gritstone Oncology, Inc and Passage BIO, Inc. and served on the board of directors of Audentes Therapeutics, Inc. from July 2013 to July 2017 and CRISPR Therapeutics AG from April 2014 to June 2019. Dr. Woiwode holds a B.A. in English and a B.S. in Chemistry from the University of California, Berkeley and a Ph.D. in Organic Chemistry as an NSF Fellow from Stanford University. - Thomas Woiwode，从2013年7月起担任我们董事会成员。Woiwode 博士2002年起在Versant Ventures担任不同的职位，2011年起担任投资合伙人；2014年7月起担任总经理。他曾在这段时间里担任许多运营职位，最近担任Okairos首席运营官。Woiwode 博士还在Versant Ventures联合创立了一家独资生物技术孵化器，为三个在Versant创立的生物技术公司担任创始首席商务官。他还曾在XenoPort, Inc.担任演技科学家；他还在数个私有企业董事会任职。Woiwode博士持有California 大学Berkeley 分校的文学士和理学位以及斯坦福大学的博士学位。
- Thomas Woiwode has served as the chairman of our board of directors since May 2019. Dr. Woiwode has been with Versant Venture Management, LLC, or Versant Ventures, a healthcare investment firm, since 2002 in various capacities, serving as a managing director since July 2014 and previously as a venture partner from June 2011 to July 2014. He has also served in a number of operating roles over this time, most recently as the chief operating officer of Okairos AG, or Okairos, a biopharmaceutical company developing genetic vaccines for major infectious diseases, from April 2011 until May 2013. Prior to Okairos, Dr. Woiwode co-founded EuroVentures, a wholly owned biotechnology incubator within Versant Ventures, and in this role, served as the founding chief business officer for three biotechnology companies created within Versant Ventures. Before joining Versant Ventures, Dr. Woiwode also served as a research scientist at XenoPort, Inc. Dr. Woiwode serves on the board of directors of several private companies and on the board of directors of four public companies, Adverum Biotechnologies, Inc., Aligos Therapeutics, Inc., Gritstone Oncology, Inc and Passage BIO, Inc. and served on the board of directors of Audentes Therapeutics, Inc. from July 2013 to July 2017 and CRISPR Therapeutics AG from April 2014 to June 2019. Dr. Woiwode holds a B.A. in English and a B.S. in Chemistry from the University of California, Berkeley and a Ph.D. in Organic Chemistry as an NSF Fellow from Stanford University.
- Carole Nuechterlein
-
Carole Nuechterlein，她担任我们的董事会成员（2014年10月以来）。她于2002年加入F. Hoffmann-La Roche Ltd.，目前担任the Roche Venture Fund的副董事兼主管。此前，她曾担任SangStat，Inc.的总法律顾问。她目前任职Lysosomal Therapeutics，Inc.的董事会。她持有Valparaiso University的学士学位，以及University of Michigan的法学博士学位。
Carole Nuechterlein has served as a member of our board of directors since March 2020. Ms. Nuechterlein joined F. Hoffmann-La Roche Ltd., a publicly traded healthcare company, in 2001 and currently serves as Head of the Roche Venture Fund. Ms. Nuechterlein began her legal career in private practice and later held senior legal positions, including as General Counsel to SangStat, Inc., a global pharmaceutical company, which was later acquired by Genzyme Corporation. Ms. Nuechterlein currently serves as a member of the boards of directors Aligos Therapeutics, Inc., a publicly traded clinical stage biopharmaceutical company. Previously, from March 2017 to June 2021 Ms. Nuechterlein served on the board of directors of Millendo Therapeutics, Inc., a publicly traded Biotech company and from October 2014 to May 2017 she served on the board of directors of AveXis, Inc., a publicly traded gene therapy company. She received a B.A. in English, History and Humanities from Valparaiso University and a J.D. from the University of Michigan. - Carole Nuechterlein，她担任我们的董事会成员（2014年10月以来）。她于2002年加入F. Hoffmann-La Roche Ltd.，目前担任the Roche Venture Fund的副董事兼主管。此前，她曾担任SangStat，Inc.的总法律顾问。她目前任职Lysosomal Therapeutics，Inc.的董事会。她持有Valparaiso University的学士学位，以及University of Michigan的法学博士学位。
- Carole Nuechterlein has served as a member of our board of directors since March 2020. Ms. Nuechterlein joined F. Hoffmann-La Roche Ltd., a publicly traded healthcare company, in 2001 and currently serves as Head of the Roche Venture Fund. Ms. Nuechterlein began her legal career in private practice and later held senior legal positions, including as General Counsel to SangStat, Inc., a global pharmaceutical company, which was later acquired by Genzyme Corporation. Ms. Nuechterlein currently serves as a member of the boards of directors Aligos Therapeutics, Inc., a publicly traded clinical stage biopharmaceutical company. Previously, from March 2017 to June 2021 Ms. Nuechterlein served on the board of directors of Millendo Therapeutics, Inc., a publicly traded Biotech company and from October 2014 to May 2017 she served on the board of directors of AveXis, Inc., a publicly traded gene therapy company. She received a B.A. in English, History and Humanities from Valparaiso University and a J.D. from the University of Michigan.
- Lawrence M. Blatt
-
Lawrence M.Blatt自2018年2月起担任我们的首席执行官兼董事会成员。在共同创立公司之前，Blatt博士于2014年11月至2018年2月担任制药公司强生公司Janssen Pharmaceuticals Companies传染病和疫苗全球主管。Blatt博士共同创立了Alios Biopharma，Inc.，这是一家生物技术公司，并从2009年1月起担任其首席执行官、总裁兼董事，直到2014年11月被Janssen Pharmaceutical Companies收购强生公司。在加入Alios之前，他从2002年到2008年担任生物技术公司Intermune，Inc.的首席科学官。Blatt博士目前任职于Reviral Ltd.的董事会，此前曾任职于Alveo Technologies，Inc.（他于2014年与Meissa Vaccines，Inc.共同创立）的董事会。Blatt博士在印第安纳大学布鲁明顿分校（Indiana University Bloomington）获得微生物学学士学位，在加州州立大学北岭分校（California State University，Northridge）获得工商管理硕士学位，在凡尔纳大学（University of La Verne）获得公共卫生管理博士学位。
Lawrence M. Blatt has served as our Chief Executive Officer and a member of our board of directors since February 2018. Prior to co-founding the Company, Dr. Blatt served as the Global Head of Infectious Diseases and Vaccines at Janssen Pharmaceutical Companies of Johnson & Johnson, a pharmaceutical company, from November 2014 to February 2018. Dr. Blatt co-founded Alios BioPharma, Inc., a biotechnology company, and served as its Chief Executive Officer, President and Director from January 2009 until its acquisition by Janssen Pharmaceutical Companies of Johnson & Johnson in November 2014. Prior to Alios, he served as Chief Scientific Officer at InterMune, Inc., a biotechnology company, from 2002 to 2008. Dr. Blatt currently serves on the board of directors of ReViral Ltd. and previously served on the boards of directors of Alveo Technologies, Inc., which he co-founded in 2014 and Meissa Vaccines, Inc. Dr. Blatt received a B.S. in Microbiology from Indiana University Bloomington, an M.B.A. from California State University, Northridge, and a Ph.D. in Public Health Administration from the University of La Verne. - Lawrence M.Blatt自2018年2月起担任我们的首席执行官兼董事会成员。在共同创立公司之前，Blatt博士于2014年11月至2018年2月担任制药公司强生公司Janssen Pharmaceuticals Companies传染病和疫苗全球主管。Blatt博士共同创立了Alios Biopharma，Inc.，这是一家生物技术公司，并从2009年1月起担任其首席执行官、总裁兼董事，直到2014年11月被Janssen Pharmaceutical Companies收购强生公司。在加入Alios之前，他从2002年到2008年担任生物技术公司Intermune，Inc.的首席科学官。Blatt博士目前任职于Reviral Ltd.的董事会，此前曾任职于Alveo Technologies，Inc.（他于2014年与Meissa Vaccines，Inc.共同创立）的董事会。Blatt博士在印第安纳大学布鲁明顿分校（Indiana University Bloomington）获得微生物学学士学位，在加州州立大学北岭分校（California State University，Northridge）获得工商管理硕士学位，在凡尔纳大学（University of La Verne）获得公共卫生管理博士学位。
- Lawrence M. Blatt has served as our Chief Executive Officer and a member of our board of directors since February 2018. Prior to co-founding the Company, Dr. Blatt served as the Global Head of Infectious Diseases and Vaccines at Janssen Pharmaceutical Companies of Johnson & Johnson, a pharmaceutical company, from November 2014 to February 2018. Dr. Blatt co-founded Alios BioPharma, Inc., a biotechnology company, and served as its Chief Executive Officer, President and Director from January 2009 until its acquisition by Janssen Pharmaceutical Companies of Johnson & Johnson in November 2014. Prior to Alios, he served as Chief Scientific Officer at InterMune, Inc., a biotechnology company, from 2002 to 2008. Dr. Blatt currently serves on the board of directors of ReViral Ltd. and previously served on the boards of directors of Alveo Technologies, Inc., which he co-founded in 2014 and Meissa Vaccines, Inc. Dr. Blatt received a B.S. in Microbiology from Indiana University Bloomington, an M.B.A. from California State University, Northridge, and a Ph.D. in Public Health Administration from the University of La Verne.
- Leonid Beigelman
-
Leonid Beigelman自2018年3月起担任总裁兼董事会成员。在共同创立该公司之前，他曾于2014年9月至2018年3月担任制药公司强生公司Janssen Pharmaceuticals Companies的药物化学Vice President兼全球发现主管，在那里他建立了核酸卓越中心。在此之前，Beigelman博士共同创立了Alios Biopharma，Inc.，并在该公司于2014年11月被强生公司的Janssen Pharmaceutical Companies收购之前担任其首席科学官。从2005年到2009年，贝格曼博士担任Intermune，Inc.丙型肝炎病毒药物研发领导团队的技术运营Vice President。2002年至2005年，Beigelman博士在Transgenomic，Inc.（一家生物技术公司）担任核酸化学Vice President。1992年至2002年在生物技术公司Ribozyme Pharmaceuticals Inc.（后成为Sirna Pharmaceuticals，Inc.）任职期间，Beigelman博士担任职位包括化学和生物化学高级总监。Beigelman博士在苏联科学院分子生物学研究所（Institute of Molecular Biology）获得生物有机化学博士学位，并在耶鲁大学医学院（Yale University Medical School）药学系完成博士后培训。
Leonid Beigelman has served as President and a member of our board of directors since March 2018. Prior to co-founding the Company, he was Vice President of Medicinal Chemistry and Global Head of Discovery of Janssen Pharmaceutical Companies of Johnson & Johnson, a pharmaceutical company, from September 2014 to March 2018 where he established the Center of Excellence in Nucleic Acids. Prior to that, Dr. Beigelman co-founded Alios BioPharma, Inc. and served as its Chief Scientific Officer before it was acquired by Janssen Pharmaceutical Companies of Johnson & Johnson in November 2014. From 2005 to 2009 Dr. Beigelman served as Vice President, Technical Operations at InterMune, Inc. leading teams in hepatitis C virus “HCV” drug discovery. From 2002 to 2005 Dr. Beigelman worked at Transgenomic, Inc., a biotechnology company, as Vice President of Nucleic Acids Chemistry. While at Ribozyme Pharmaceuticals Inc., a biotechnology company, from 1992 to 2002 (which became SiRNA Pharmaceuticals, Inc.), Dr. Beigelman assumed positions including Senior Director of Chemistry and Biochemistry. Dr. Beigelman received his Ph.D. in Bioorganic Chemistry from The Institute of Molecular Biology (USSR Academy of Sciences) and completed his post-doctoral training at the Department of Pharmacology, Yale University Medical school. - Leonid Beigelman自2018年3月起担任总裁兼董事会成员。在共同创立该公司之前，他曾于2014年9月至2018年3月担任制药公司强生公司Janssen Pharmaceuticals Companies的药物化学Vice President兼全球发现主管，在那里他建立了核酸卓越中心。在此之前，Beigelman博士共同创立了Alios Biopharma，Inc.，并在该公司于2014年11月被强生公司的Janssen Pharmaceutical Companies收购之前担任其首席科学官。从2005年到2009年，贝格曼博士担任Intermune，Inc.丙型肝炎病毒药物研发领导团队的技术运营Vice President。2002年至2005年，Beigelman博士在Transgenomic，Inc.（一家生物技术公司）担任核酸化学Vice President。1992年至2002年在生物技术公司Ribozyme Pharmaceuticals Inc.（后成为Sirna Pharmaceuticals，Inc.）任职期间，Beigelman博士担任职位包括化学和生物化学高级总监。Beigelman博士在苏联科学院分子生物学研究所（Institute of Molecular Biology）获得生物有机化学博士学位，并在耶鲁大学医学院（Yale University Medical School）药学系完成博士后培训。
- Leonid Beigelman has served as President and a member of our board of directors since March 2018. Prior to co-founding the Company, he was Vice President of Medicinal Chemistry and Global Head of Discovery of Janssen Pharmaceutical Companies of Johnson & Johnson, a pharmaceutical company, from September 2014 to March 2018 where he established the Center of Excellence in Nucleic Acids. Prior to that, Dr. Beigelman co-founded Alios BioPharma, Inc. and served as its Chief Scientific Officer before it was acquired by Janssen Pharmaceutical Companies of Johnson & Johnson in November 2014. From 2005 to 2009 Dr. Beigelman served as Vice President, Technical Operations at InterMune, Inc. leading teams in hepatitis C virus “HCV” drug discovery. From 2002 to 2005 Dr. Beigelman worked at Transgenomic, Inc., a biotechnology company, as Vice President of Nucleic Acids Chemistry. While at Ribozyme Pharmaceuticals Inc., a biotechnology company, from 1992 to 2002 (which became SiRNA Pharmaceuticals, Inc.), Dr. Beigelman assumed positions including Senior Director of Chemistry and Biochemistry. Dr. Beigelman received his Ph.D. in Bioorganic Chemistry from The Institute of Molecular Biology (USSR Academy of Sciences) and completed his post-doctoral training at the Department of Pharmacology, Yale University Medical school.
- Kathleen Sereda Glaub
-
Kathleen Sereda Glaub自2019年10月起担任我们的董事会成员。Glaub女士自2018年10月起担任生物技术公司Curasen Therapeutics，Inc.的联合创始人兼执行主席。她还担任生物技术公司Escient Pharmaceuticals，Inc.和丹麦生物技术公司IO Biotech APS的董事会董事。她曾于2014年9月至2019年9月担任上市蛋白质工程公司Codexis，Inc.的董事会成员，并于2013年11月至2016年10月担任生物技术公司Afferent Pharmaceuticals，Inc.的董事会成员。Glaub女士还于2014年8月至2016年10月担任Afferent Pharmaceuticals首席执行官。Glaub女士还在Plexxicon Inc.担任了12年的总裁。此前，她曾担任Cell Genesys，Inc.（一家生物技术公司）的高级副总裁和首席财务官、Genentech，Inc.（一家生物技术公司）的财务主管，以及英特尔公司（一家技术公司）的多种财务和财务职务。Glaub女士在加州大学伯克利分校（University of California，Berkeley）获得文学学士学位，在西北大学凯洛格管理学院（Northwestern University Kellogg School of Management）获得工商管理硕士学位。
Kathleen Sereda Glaub,is co-founder and executive chair for the board of CuraSen Therapeutics, Inc., a biotechnology company, a position she has held since October 2018. From November 2013 until the acquisition of the company by Merck in July 2016, Ms. Glaub served as a director on the board of Afferent Pharmaceuticals. She also served as the Chief Executive Officer of Afferent Pharmaceuticals from August 2014 to October 2016. Previously, she served as president of Plexxikon, Inc. from November 2001 to May 2013. Prior to Plexxikon, Ms. Glaub held positions as senior vice president and chief financial officer of Cell Genesys, Inc., a public biotechnology company, treasurer of Genentech, Inc., a public biotechnology company, and various finance and treasury roles with Intel Corporation, a public technology company. She also serves as a director and chair on the board of Escient Pharmaceuticals, Inc., a private biotechnology company. She previously served on the boards of Codexis, Inc., a publicly traded protein engineering and therapeutics company, and Aligos Pharmaceuticals, Inc., a publicly traded biotechnology company. Ms. Glaub also previously served as a member of the investment advisory board to the Bailard Healthcare Fund. Ms. Glaub received a B.A. from the University of California, Berkeley and an M.B.A. from Northwestern University Kellogg School of Management. - Kathleen Sereda Glaub自2019年10月起担任我们的董事会成员。Glaub女士自2018年10月起担任生物技术公司Curasen Therapeutics，Inc.的联合创始人兼执行主席。她还担任生物技术公司Escient Pharmaceuticals，Inc.和丹麦生物技术公司IO Biotech APS的董事会董事。她曾于2014年9月至2019年9月担任上市蛋白质工程公司Codexis，Inc.的董事会成员，并于2013年11月至2016年10月担任生物技术公司Afferent Pharmaceuticals，Inc.的董事会成员。Glaub女士还于2014年8月至2016年10月担任Afferent Pharmaceuticals首席执行官。Glaub女士还在Plexxicon Inc.担任了12年的总裁。此前，她曾担任Cell Genesys，Inc.（一家生物技术公司）的高级副总裁和首席财务官、Genentech，Inc.（一家生物技术公司）的财务主管，以及英特尔公司（一家技术公司）的多种财务和财务职务。Glaub女士在加州大学伯克利分校（University of California，Berkeley）获得文学学士学位，在西北大学凯洛格管理学院（Northwestern University Kellogg School of Management）获得工商管理硕士学位。
- Kathleen Sereda Glaub,is co-founder and executive chair for the board of CuraSen Therapeutics, Inc., a biotechnology company, a position she has held since October 2018. From November 2013 until the acquisition of the company by Merck in July 2016, Ms. Glaub served as a director on the board of Afferent Pharmaceuticals. She also served as the Chief Executive Officer of Afferent Pharmaceuticals from August 2014 to October 2016. Previously, she served as president of Plexxikon, Inc. from November 2001 to May 2013. Prior to Plexxikon, Ms. Glaub held positions as senior vice president and chief financial officer of Cell Genesys, Inc., a public biotechnology company, treasurer of Genentech, Inc., a public biotechnology company, and various finance and treasury roles with Intel Corporation, a public technology company. She also serves as a director and chair on the board of Escient Pharmaceuticals, Inc., a private biotechnology company. She previously served on the boards of Codexis, Inc., a publicly traded protein engineering and therapeutics company, and Aligos Pharmaceuticals, Inc., a publicly traded biotechnology company. Ms. Glaub also previously served as a member of the investment advisory board to the Bailard Healthcare Fund. Ms. Glaub received a B.A. from the University of California, Berkeley and an M.B.A. from Northwestern University Kellogg School of Management.
- K. Peter Hirth
-
K. Peter Hirth，博士生，自2013年6月曾担任公司董事会成员。从2000年到2013年4月，他曾担任被Daiichi Sankyo 公司收购的Plexxikon公司的联合创始人和首席执行官。从1991年至2000年Hirth博士曾在Sugen公司担任多个职务，最近担任的是公司总裁，该公司是一家药物研发公司，目前是辉瑞公司（Pfizer）的一部分。在加入Sugen公司以前，他在Boehringer Mannheim公司担任副总裁，并作为马克斯普朗克研究所（the Max Planck Institute）的研究科学家。Hirth博士在德国Heilbronn，Hirth博士在位于德国海德堡的罗伯特·迈耶体育馆收到的arbitu，并且是海德堡大学（Heidelberg University）分子遗传学博士及美国加州大学圣地亚哥分校（the University of California, San Diego）的发育生物学的博士后。
K. Peter Hirth has served as a member of our board of directors since August 2018. In 2001 Dr. Hirth co-founded Plexxikon, Inc., a pharmaceutical company, and served as its Chief Executive Officer until April 2013. Dr. Hirth currently serves on the boards of directors of Vaxcyte, Inc., a publicly traded biotechnology company, and several private companies. Dr. Hirth holds a M.Sc. and Ph.D. in Molecular Genetics from Heidelberg University, Germany and completed his post-doctoral work at the University of California, San Diego. - K. Peter Hirth，博士生，自2013年6月曾担任公司董事会成员。从2000年到2013年4月，他曾担任被Daiichi Sankyo 公司收购的Plexxikon公司的联合创始人和首席执行官。从1991年至2000年Hirth博士曾在Sugen公司担任多个职务，最近担任的是公司总裁，该公司是一家药物研发公司，目前是辉瑞公司（Pfizer）的一部分。在加入Sugen公司以前，他在Boehringer Mannheim公司担任副总裁，并作为马克斯普朗克研究所（the Max Planck Institute）的研究科学家。Hirth博士在德国Heilbronn，Hirth博士在位于德国海德堡的罗伯特·迈耶体育馆收到的arbitu，并且是海德堡大学（Heidelberg University）分子遗传学博士及美国加州大学圣地亚哥分校（the University of California, San Diego）的发育生物学的博士后。
- K. Peter Hirth has served as a member of our board of directors since August 2018. In 2001 Dr. Hirth co-founded Plexxikon, Inc., a pharmaceutical company, and served as its Chief Executive Officer until April 2013. Dr. Hirth currently serves on the boards of directors of Vaxcyte, Inc., a publicly traded biotechnology company, and several private companies. Dr. Hirth holds a M.Sc. and Ph.D. in Molecular Genetics from Heidelberg University, Germany and completed his post-doctoral work at the University of California, San Diego.
- Jack B. Nielsen
-
Jack B. Nielsen，自2006年10月起担任我们的董事。Nielsen先生自2001年起就在the Novo A/S organization及其风险活动方面任职，最近被聘为合伙人。2006年至2012年，Nielsen先生被Novo Ventures US Inc.聘为合伙人。1990年至2001年，他在Novo Nordisk（2000年成为Novozymes A/S）担任多个职位。Nielsen先生目前是Akebia Therapeutics, Inc., Alios BioPharma Inc., Apollo Endosurgery Inc., BioClin Therapeutics Inc., Reata Pharmaceuticals Inc.和Tobira Therapeutics Inc.的董事。 Nielsen先生于1990年获得了Technical University of Denmark的硕士学位，2000年获得哥本哈根the Center for Technology, Economics and Management的技术管理硕士学位。
Jack B. Nielsen has served as a member our board of directors since August 2018. Since August 2017 Mr. Nielsen has also served as a Managing Director at Vivo Capital LLC, a healthcare focused investment firm. Prior to March, 2017 Mr. Nielsen worked within the Novo Holdings A/S organization and its venture activities since 2001 in several roles, most recently being employed as a Senior Partner based in Copenhagen, Denmark. From 2006 to 2012 Mr. Nielsen was employed as a Partner at Novo Ventures US Inc. in San Francisco, where he established the office which provides certain consultancy services to Novo Holdings A/S. Mr. Nielsen is currently a member of the board of directors of Reata Pharmaceuticals, Inc. and ALX Oncology Holdings Inc., both of which are publicly traded companies, and a number of private companies. Mr. Nielsen, in the past, has served on the boards of directors of Akebia Therapeutics, Inc., Crinetics Pharmaceuticals, Inc., Merus, N.V. and Apollo Endosurgery, Inc., each of which is publicly traded. Mr. Nielsen received a M.Sc. in Chemical Engineering from the Technical University of Denmark and a Masters in Management of Technology and Economics from the Center for Technology, Economics and Management, Technical University of Denmark. - Jack B. Nielsen，自2006年10月起担任我们的董事。Nielsen先生自2001年起就在the Novo A/S organization及其风险活动方面任职，最近被聘为合伙人。2006年至2012年，Nielsen先生被Novo Ventures US Inc.聘为合伙人。1990年至2001年，他在Novo Nordisk（2000年成为Novozymes A/S）担任多个职位。Nielsen先生目前是Akebia Therapeutics, Inc., Alios BioPharma Inc., Apollo Endosurgery Inc., BioClin Therapeutics Inc., Reata Pharmaceuticals Inc.和Tobira Therapeutics Inc.的董事。 Nielsen先生于1990年获得了Technical University of Denmark的硕士学位，2000年获得哥本哈根the Center for Technology, Economics and Management的技术管理硕士学位。
- Jack B. Nielsen has served as a member our board of directors since August 2018. Since August 2017 Mr. Nielsen has also served as a Managing Director at Vivo Capital LLC, a healthcare focused investment firm. Prior to March, 2017 Mr. Nielsen worked within the Novo Holdings A/S organization and its venture activities since 2001 in several roles, most recently being employed as a Senior Partner based in Copenhagen, Denmark. From 2006 to 2012 Mr. Nielsen was employed as a Partner at Novo Ventures US Inc. in San Francisco, where he established the office which provides certain consultancy services to Novo Holdings A/S. Mr. Nielsen is currently a member of the board of directors of Reata Pharmaceuticals, Inc. and ALX Oncology Holdings Inc., both of which are publicly traded companies, and a number of private companies. Mr. Nielsen, in the past, has served on the boards of directors of Akebia Therapeutics, Inc., Crinetics Pharmaceuticals, Inc., Merus, N.V. and Apollo Endosurgery, Inc., each of which is publicly traded. Mr. Nielsen received a M.Sc. in Chemical Engineering from the Technical University of Denmark and a Masters in Management of Technology and Economics from the Center for Technology, Economics and Management, Technical University of Denmark.
高管简历
中英对照 | 中文 | 英文- Lawrence M. Blatt
Lawrence M.Blatt自2018年2月起担任我们的首席执行官兼董事会成员。在共同创立公司之前，Blatt博士于2014年11月至2018年2月担任制药公司强生公司Janssen Pharmaceuticals Companies传染病和疫苗全球主管。Blatt博士共同创立了Alios Biopharma，Inc.，这是一家生物技术公司，并从2009年1月起担任其首席执行官、总裁兼董事，直到2014年11月被Janssen Pharmaceutical Companies收购强生公司。在加入Alios之前，他从2002年到2008年担任生物技术公司Intermune，Inc.的首席科学官。Blatt博士目前任职于Reviral Ltd.的董事会，此前曾任职于Alveo Technologies，Inc.（他于2014年与Meissa Vaccines，Inc.共同创立）的董事会。Blatt博士在印第安纳大学布鲁明顿分校（Indiana University Bloomington）获得微生物学学士学位，在加州州立大学北岭分校（California State University，Northridge）获得工商管理硕士学位，在凡尔纳大学（University of La Verne）获得公共卫生管理博士学位。
Lawrence M. Blatt has served as our Chief Executive Officer and a member of our board of directors since February 2018. Prior to co-founding the Company, Dr. Blatt served as the Global Head of Infectious Diseases and Vaccines at Janssen Pharmaceutical Companies of Johnson & Johnson, a pharmaceutical company, from November 2014 to February 2018. Dr. Blatt co-founded Alios BioPharma, Inc., a biotechnology company, and served as its Chief Executive Officer, President and Director from January 2009 until its acquisition by Janssen Pharmaceutical Companies of Johnson & Johnson in November 2014. Prior to Alios, he served as Chief Scientific Officer at InterMune, Inc., a biotechnology company, from 2002 to 2008. Dr. Blatt currently serves on the board of directors of ReViral Ltd. and previously served on the boards of directors of Alveo Technologies, Inc., which he co-founded in 2014 and Meissa Vaccines, Inc. Dr. Blatt received a B.S. in Microbiology from Indiana University Bloomington, an M.B.A. from California State University, Northridge, and a Ph.D. in Public Health Administration from the University of La Verne.- Lawrence M.Blatt自2018年2月起担任我们的首席执行官兼董事会成员。在共同创立公司之前，Blatt博士于2014年11月至2018年2月担任制药公司强生公司Janssen Pharmaceuticals Companies传染病和疫苗全球主管。Blatt博士共同创立了Alios Biopharma，Inc.，这是一家生物技术公司，并从2009年1月起担任其首席执行官、总裁兼董事，直到2014年11月被Janssen Pharmaceutical Companies收购强生公司。在加入Alios之前，他从2002年到2008年担任生物技术公司Intermune，Inc.的首席科学官。Blatt博士目前任职于Reviral Ltd.的董事会，此前曾任职于Alveo Technologies，Inc.（他于2014年与Meissa Vaccines，Inc.共同创立）的董事会。Blatt博士在印第安纳大学布鲁明顿分校（Indiana University Bloomington）获得微生物学学士学位，在加州州立大学北岭分校（California State University，Northridge）获得工商管理硕士学位，在凡尔纳大学（University of La Verne）获得公共卫生管理博士学位。
- Lawrence M. Blatt has served as our Chief Executive Officer and a member of our board of directors since February 2018. Prior to co-founding the Company, Dr. Blatt served as the Global Head of Infectious Diseases and Vaccines at Janssen Pharmaceutical Companies of Johnson & Johnson, a pharmaceutical company, from November 2014 to February 2018. Dr. Blatt co-founded Alios BioPharma, Inc., a biotechnology company, and served as its Chief Executive Officer, President and Director from January 2009 until its acquisition by Janssen Pharmaceutical Companies of Johnson & Johnson in November 2014. Prior to Alios, he served as Chief Scientific Officer at InterMune, Inc., a biotechnology company, from 2002 to 2008. Dr. Blatt currently serves on the board of directors of ReViral Ltd. and previously served on the boards of directors of Alveo Technologies, Inc., which he co-founded in 2014 and Meissa Vaccines, Inc. Dr. Blatt received a B.S. in Microbiology from Indiana University Bloomington, an M.B.A. from California State University, Northridge, and a Ph.D. in Public Health Administration from the University of La Verne.
- Leonid Beigelman
Leonid Beigelman自2018年3月起担任总裁兼董事会成员。在共同创立该公司之前，他曾于2014年9月至2018年3月担任制药公司强生公司Janssen Pharmaceuticals Companies的药物化学Vice President兼全球发现主管，在那里他建立了核酸卓越中心。在此之前，Beigelman博士共同创立了Alios Biopharma，Inc.，并在该公司于2014年11月被强生公司的Janssen Pharmaceutical Companies收购之前担任其首席科学官。从2005年到2009年，贝格曼博士担任Intermune，Inc.丙型肝炎病毒药物研发领导团队的技术运营Vice President。2002年至2005年，Beigelman博士在Transgenomic，Inc.（一家生物技术公司）担任核酸化学Vice President。1992年至2002年在生物技术公司Ribozyme Pharmaceuticals Inc.（后成为Sirna Pharmaceuticals，Inc.）任职期间，Beigelman博士担任职位包括化学和生物化学高级总监。Beigelman博士在苏联科学院分子生物学研究所（Institute of Molecular Biology）获得生物有机化学博士学位，并在耶鲁大学医学院（Yale University Medical School）药学系完成博士后培训。
Leonid Beigelman has served as President and a member of our board of directors since March 2018. Prior to co-founding the Company, he was Vice President of Medicinal Chemistry and Global Head of Discovery of Janssen Pharmaceutical Companies of Johnson & Johnson, a pharmaceutical company, from September 2014 to March 2018 where he established the Center of Excellence in Nucleic Acids. Prior to that, Dr. Beigelman co-founded Alios BioPharma, Inc. and served as its Chief Scientific Officer before it was acquired by Janssen Pharmaceutical Companies of Johnson & Johnson in November 2014. From 2005 to 2009 Dr. Beigelman served as Vice President, Technical Operations at InterMune, Inc. leading teams in hepatitis C virus “HCV” drug discovery. From 2002 to 2005 Dr. Beigelman worked at Transgenomic, Inc., a biotechnology company, as Vice President of Nucleic Acids Chemistry. While at Ribozyme Pharmaceuticals Inc., a biotechnology company, from 1992 to 2002 (which became SiRNA Pharmaceuticals, Inc.), Dr. Beigelman assumed positions including Senior Director of Chemistry and Biochemistry. Dr. Beigelman received his Ph.D. in Bioorganic Chemistry from The Institute of Molecular Biology (USSR Academy of Sciences) and completed his post-doctoral training at the Department of Pharmacology, Yale University Medical school.- Leonid Beigelman自2018年3月起担任总裁兼董事会成员。在共同创立该公司之前，他曾于2014年9月至2018年3月担任制药公司强生公司Janssen Pharmaceuticals Companies的药物化学Vice President兼全球发现主管，在那里他建立了核酸卓越中心。在此之前，Beigelman博士共同创立了Alios Biopharma，Inc.，并在该公司于2014年11月被强生公司的Janssen Pharmaceutical Companies收购之前担任其首席科学官。从2005年到2009年，贝格曼博士担任Intermune，Inc.丙型肝炎病毒药物研发领导团队的技术运营Vice President。2002年至2005年，Beigelman博士在Transgenomic，Inc.（一家生物技术公司）担任核酸化学Vice President。1992年至2002年在生物技术公司Ribozyme Pharmaceuticals Inc.（后成为Sirna Pharmaceuticals，Inc.）任职期间，Beigelman博士担任职位包括化学和生物化学高级总监。Beigelman博士在苏联科学院分子生物学研究所（Institute of Molecular Biology）获得生物有机化学博士学位，并在耶鲁大学医学院（Yale University Medical School）药学系完成博士后培训。
- Leonid Beigelman has served as President and a member of our board of directors since March 2018. Prior to co-founding the Company, he was Vice President of Medicinal Chemistry and Global Head of Discovery of Janssen Pharmaceutical Companies of Johnson & Johnson, a pharmaceutical company, from September 2014 to March 2018 where he established the Center of Excellence in Nucleic Acids. Prior to that, Dr. Beigelman co-founded Alios BioPharma, Inc. and served as its Chief Scientific Officer before it was acquired by Janssen Pharmaceutical Companies of Johnson & Johnson in November 2014. From 2005 to 2009 Dr. Beigelman served as Vice President, Technical Operations at InterMune, Inc. leading teams in hepatitis C virus “HCV” drug discovery. From 2002 to 2005 Dr. Beigelman worked at Transgenomic, Inc., a biotechnology company, as Vice President of Nucleic Acids Chemistry. While at Ribozyme Pharmaceuticals Inc., a biotechnology company, from 1992 to 2002 (which became SiRNA Pharmaceuticals, Inc.), Dr. Beigelman assumed positions including Senior Director of Chemistry and Biochemistry. Dr. Beigelman received his Ph.D. in Bioorganic Chemistry from The Institute of Molecular Biology (USSR Academy of Sciences) and completed his post-doctoral training at the Department of Pharmacology, Yale University Medical school.
- Lesley Ann Calhoun
Lesley Ann Calhoun自2020年6月起担任我们首席财务官的执行Vice President。2016年8月至2020年6月，卡尔霍恩女士曾在药物发现，开发和商业阶段的生物制药公司全球血液疗法公司担任多个职位，包括最近担任高级副总裁，财务与管理和首席会计官。在担任这些职务之前，Calhoun女士于2013年1月至2015年9月担任商业阶段生物制药公司HyperionTherapeutics，Inc.的财务Vice President，在该公司于2015年5月被制药公司Horizon Pharma plc收购后继续担任该职务。2005年8月至2013年1月，卡尔霍恩女士还曾担任生物制药公司Innoviva，Inc.（前身为Theravance，Inc.）的高级财务总监兼公司财务总监。在她职业生涯的早期，Calhoun女士从1989年到2001年是Deloitte&Touche LLP审计实践的成员。Calhoun女士在旧金山州立大学商学院（San Francisco State University，College of Business）获得工商管理学士学位，并专注于会计，是一名注册会计师（不活跃）。
Lesley Ann Calhoun has served as our Executive Vice President, Chief Financial Officer since June 2020. From August 2016 to June 2020 Ms. Calhoun served in various roles at Global Blood Therapeutics, Inc., a drug discovery, development and commercial-stage biopharmaceutical company, including most recently as Senior Vice President, Finance & Administration and Chief Accounting Officer. Prior to these roles, Ms. Calhoun served as Vice President of Finance at Hyperion Therapeutics, Inc., a commercial stage biopharmaceutical company, from January 2013 to September 2015 continuing in her role after it was acquired by Horizon Pharma plc, a pharmaceutical company, in May 2015. Ms. Calhoun also previously served as Senior Director of Finance, Corporate Controller at Innoviva, Inc. formerly Theravance, Inc., a biopharmaceutical company, from August 2005 to January 2013. Earlier in her career, Ms. Calhoun was a member of the audit practice of Deloitte & Touche LLP from 1989 to 2001. Ms. Calhoun received her B.S. in Business Administration with a concentration in Accounting from San Francisco State University, College of Business and is a Certified Public Accountant (inactive).- Lesley Ann Calhoun自2020年6月起担任我们首席财务官的执行Vice President。2016年8月至2020年6月，卡尔霍恩女士曾在药物发现，开发和商业阶段的生物制药公司全球血液疗法公司担任多个职位，包括最近担任高级副总裁，财务与管理和首席会计官。在担任这些职务之前，Calhoun女士于2013年1月至2015年9月担任商业阶段生物制药公司HyperionTherapeutics，Inc.的财务Vice President，在该公司于2015年5月被制药公司Horizon Pharma plc收购后继续担任该职务。2005年8月至2013年1月，卡尔霍恩女士还曾担任生物制药公司Innoviva，Inc.（前身为Theravance，Inc.）的高级财务总监兼公司财务总监。在她职业生涯的早期，Calhoun女士从1989年到2001年是Deloitte&Touche LLP审计实践的成员。Calhoun女士在旧金山州立大学商学院（San Francisco State University，College of Business）获得工商管理学士学位，并专注于会计，是一名注册会计师（不活跃）。
- Lesley Ann Calhoun has served as our Executive Vice President, Chief Financial Officer since June 2020. From August 2016 to June 2020 Ms. Calhoun served in various roles at Global Blood Therapeutics, Inc., a drug discovery, development and commercial-stage biopharmaceutical company, including most recently as Senior Vice President, Finance & Administration and Chief Accounting Officer. Prior to these roles, Ms. Calhoun served as Vice President of Finance at Hyperion Therapeutics, Inc., a commercial stage biopharmaceutical company, from January 2013 to September 2015 continuing in her role after it was acquired by Horizon Pharma plc, a pharmaceutical company, in May 2015. Ms. Calhoun also previously served as Senior Director of Finance, Corporate Controller at Innoviva, Inc. formerly Theravance, Inc., a biopharmaceutical company, from August 2005 to January 2013. Earlier in her career, Ms. Calhoun was a member of the audit practice of Deloitte & Touche LLP from 1989 to 2001. Ms. Calhoun received her B.S. in Business Administration with a concentration in Accounting from San Francisco State University, College of Business and is a Certified Public Accountant (inactive).
- Lucinda Y. Quan
Lucinda Y.Quan自2018年3月起担任公司执行Vice President、首席商务官兼总法律顾问。在加入公司之前，全女士于2016年1月至2018年4月担任跨国制药公司默克公司（Merck&Co.）西海岸创新枢纽交易，业务发展与许可执行董事。Quan女士于2013年11月至2016年1月担任Alios Biopharma，Inc.的法律事务主管Vice President，该公司于2014年11月被制药公司强生公司的Janssen Pharmaceuticals Companies收购。2004年9月至2013年11月，她还担任罗氏于2014年9月收购的Intermune，Inc.的Vice President、法律事务和副总法律顾问。在Intermune，Inc.之前，全女士在包括Clifford Chance LLP在内的多家律师事务所从事了7年的私人执业，然后过渡到内部律师事务所。Quan女士在加州大学洛杉矶分校（University of California，Los Angeles）获得商业经济学学士学位和法学博士学位。
Lucinda Y. Quan has served as our Executive Vice President, Chief Business Officer & General Counsel since March 2018. Prior to joining the Company, Ms. Quan served as the Executive Director of Transactions, Business Development & Licensing at the West Coast Innovations Hub of Merck & Co., a multinational pharmaceutical company, from January 2016 to April 2018. From November 2013 to January 2016 Ms. Quan served as Vice President, Head of Legal Affairs at Alios BioPharma, Inc., which was acquired by Janssen Pharmaceutical Companies of Johnson & Johnson, a pharmaceutical company, in November 2014. She also served as Vice President, Legal Affairs & Associate General Counsel at InterMune, Inc. acquired by Roche in September 2014 from September 2004 to November 2013. Prior to InterMune, Inc., Ms. Quan spent seven years in private practice at various law firms, including Clifford Chance LLP, before transitioning to in-house. Ms. Quan received both her B.A. in Business Economics and J.D. from the University of California, Los Angeles.- Lucinda Y.Quan自2018年3月起担任公司执行Vice President、首席商务官兼总法律顾问。在加入公司之前，全女士于2016年1月至2018年4月担任跨国制药公司默克公司（Merck&Co.）西海岸创新枢纽交易，业务发展与许可执行董事。Quan女士于2013年11月至2016年1月担任Alios Biopharma，Inc.的法律事务主管Vice President，该公司于2014年11月被制药公司强生公司的Janssen Pharmaceuticals Companies收购。2004年9月至2013年11月，她还担任罗氏于2014年9月收购的Intermune，Inc.的Vice President、法律事务和副总法律顾问。在Intermune，Inc.之前，全女士在包括Clifford Chance LLP在内的多家律师事务所从事了7年的私人执业，然后过渡到内部律师事务所。Quan女士在加州大学洛杉矶分校（University of California，Los Angeles）获得商业经济学学士学位和法学博士学位。
- Lucinda Y. Quan has served as our Executive Vice President, Chief Business Officer & General Counsel since March 2018. Prior to joining the Company, Ms. Quan served as the Executive Director of Transactions, Business Development & Licensing at the West Coast Innovations Hub of Merck & Co., a multinational pharmaceutical company, from January 2016 to April 2018. From November 2013 to January 2016 Ms. Quan served as Vice President, Head of Legal Affairs at Alios BioPharma, Inc., which was acquired by Janssen Pharmaceutical Companies of Johnson & Johnson, a pharmaceutical company, in November 2014. She also served as Vice President, Legal Affairs & Associate General Counsel at InterMune, Inc. acquired by Roche in September 2014 from September 2004 to November 2013. Prior to InterMune, Inc., Ms. Quan spent seven years in private practice at various law firms, including Clifford Chance LLP, before transitioning to in-house. Ms. Quan received both her B.A. in Business Economics and J.D. from the University of California, Los Angeles.
- Julian A. Symons
Julian A.Symons自2018年5月起担任我们的执行Vice President兼首席科学官。2010年1月至2015年3月，Symons博士在Alios Biopharma，Inc.担任多个职位，2014年11月，Alios Biopharma，Inc.被制药公司强生公司的Janssen Pharmaceuticals Companies收购，2013年1月至2015年3月担任产品开发，2015年3月至2018年4月担任呼吸道感染疾病领域研发负责人Vice President。在Alios Biopharma，Inc.任职之前，Symons博士曾在F.Hoffman-La Roche Ltd的制药部门和爱丁堡大学医学系任职（1986-1990年）谢菲尔德大学（1990-1994年）和威廉·邓恩爵士病理学学院，牛津大学（1994-1999年）。Symons博士获得了理学学士学位。我在英国中央兰开夏大学获得生物化学和生理学荣誉学士学位，并获得哲学博士学位。the University of York，UK免疫学和自身免疫学学位。
Julian A. Symons has served as our Executive Vice President, Chief Scientific Officer since May 2018. Prior to joining the Company, from January 2010 to March 2015 Dr. Symons served in various roles at Alios BioPharma, Inc., which was acquired by Janssen Pharmaceutical Companies of Johnson & Johnson, a pharmaceutical company, in November 2014 including Senior Director, Product Development from January 2013 to March 2015 and Vice President, Disease Area Research & Development Leader, Respiratory Infections from March 2015 to April 2018. Prior to his time with Alios BioPharma, Inc., Dr. Symons held positions with the Pharmaceutical Division of F. Hoffman-La Roche Ltd and the Departments of Medicine at the University of Edinburgh 1986 - 1990 University of Sheffield (1990 - 1994) and the Sir William Dunn School of Pathology, University of Oxford (1994 - 1999). Dr. Symons received a B.Sc. (Hons) I in Biochemistry and Physiology from the University of Central Lancashire, UK and a D.Phil. in Immunology and Autoimmunity from the University of York, UK.- Julian A.Symons自2018年5月起担任我们的执行Vice President兼首席科学官。2010年1月至2015年3月，Symons博士在Alios Biopharma，Inc.担任多个职位，2014年11月，Alios Biopharma，Inc.被制药公司强生公司的Janssen Pharmaceuticals Companies收购，2013年1月至2015年3月担任产品开发，2015年3月至2018年4月担任呼吸道感染疾病领域研发负责人Vice President。在Alios Biopharma，Inc.任职之前，Symons博士曾在F.Hoffman-La Roche Ltd的制药部门和爱丁堡大学医学系任职（1986-1990年）谢菲尔德大学（1990-1994年）和威廉·邓恩爵士病理学学院，牛津大学（1994-1999年）。Symons博士获得了理学学士学位。我在英国中央兰开夏大学获得生物化学和生理学荣誉学士学位，并获得哲学博士学位。the University of York，UK免疫学和自身免疫学学位。
- Julian A. Symons has served as our Executive Vice President, Chief Scientific Officer since May 2018. Prior to joining the Company, from January 2010 to March 2015 Dr. Symons served in various roles at Alios BioPharma, Inc., which was acquired by Janssen Pharmaceutical Companies of Johnson & Johnson, a pharmaceutical company, in November 2014 including Senior Director, Product Development from January 2013 to March 2015 and Vice President, Disease Area Research & Development Leader, Respiratory Infections from March 2015 to April 2018. Prior to his time with Alios BioPharma, Inc., Dr. Symons held positions with the Pharmaceutical Division of F. Hoffman-La Roche Ltd and the Departments of Medicine at the University of Edinburgh 1986 - 1990 University of Sheffield (1990 - 1994) and the Sir William Dunn School of Pathology, University of Oxford (1994 - 1999). Dr. Symons received a B.Sc. (Hons) I in Biochemistry and Physiology from the University of Central Lancashire, UK and a D.Phil. in Immunology and Autoimmunity from the University of York, UK.